Igor’s creative director in today’s San Francisco Business Times
It’s a bad time for A-list biotech companies.
From Anesiva to Avigen, a number of biotech companies with names starting with an “a” and including a “v” are facing tough times. So is it the name — or the companies — that are not so sweet?
Avigen Inc. of Alameda will liquidate after a five-month war of words with its largest shareholders. Anesiva Inc. of South San Francisco, which on March 25 said it has enough cash to last into April, hopes to gross $3 million in a rights offering. And Avicena Group Inc. of Palo Alto, while holding on with $1 million raised from foreign investors last fall, was kicked off the NASDAQ bulletin board back in September and hasn’t filed a financial statement with the SEC since May 2008.
“So many biotechs started with that (“a”) pattern, so a disproportionate number are failing now because there are more of them,” said Jay Jurisich, creative director and cofounder of Igor Inc., a San Francisco naming and branding agency.
You can read the rest of the article here.
Read more: naming companies, naming company, naming consultants